AaiPharma Inc., of Wilmington, N.C., appointed Edward Morris executive vice president, clinical trials division of AAI International.
ActivX Biosciences Inc., of La Jolla, Calif., promoted Jonathan Burbaum to vice president, advanced technology.
Advanced Viral Research Corp., of Yonkers, N.Y., appointed Richard Kent to its board and added Sidney Pestka to its scientific advisory board.
Aegera Therapeutics Inc., of Montreal, appointed Donald Olds vice president, finance and chief financial officer.
AEterna Laboratories Inc., of Quebec City, Quebec, appointed Claude Cardinal vice president of technical operations.
Alpha Therapeutic Corp., of Los Angeles, appointed Thomas Speace vice president, worldwide marketing and international operations.
Applied Molecular Evolution Inc., of San Diego, elected Raymond Dittamore, Coleman Owen and William Respess to its board.
BioImage A/S, of Copenhagen, Denmark, named Edwin Moses chair of its board, said Axel Ullrich will chair its scientific advisory board and appointed Barry Ross to its board.
Carrington Laboratories Inc., of Irving, Texas, said its subsidiary, DelSite Biotechnologies Inc., appointed Charles McCormick to its scientific advisory board.
Cognetix Inc., of Salt Lake City, promoted Carl Roland to vice president, clinical development, and Vicki Farrar to vice president, intellectual property.
Draxis Health Inc., of Mississauga, Ontario, appointed Jim Garner acting president of Draxis Pharma Inc.
EmerGen Inc., of Salt Lake City, appointed Arlene Morris to its board.
Endovasc Ltd., of Montgomery, Texas, formed a scientific advisory board consisting of James Regan, Michel Henry, Martin Leon, Daniel Burkhoff, Charles Seidel, Hiroko Yoshida, Alan Burns and Dmitri Kirpotin.
GenoSpectra Inc., of Fremont, Calif., appointed Gary McMaster chief scientific officer.
GlycoGenesys Inc., of Boston, added Jean Nichols as interim chief scientific officer and Mark Staples as vice president of development and manufacturing.
Immune Network Ltd., of Vancouver, British Columbia, named Howard Feldman and Serge Gauthier to its clinical advisory team.
Immuno-Designed Molecules SA, of Paris, added Michael Lotze to its scientific advisory board.
Nanosys Inc., of Palo Alto, Calif., added Wallace Parce as chief technology officer and vice president of research.
Neokimia Inc., of Sherbrooke, Quebec, appointed Robert Déziel senior director, research.
PhageTech Inc., of Montreal, appointed Jinzi Jason vice president, research and development; Christian Belisle vice president, finance; and Serge Lapointe director of intellectual property.
PPD Inc., of Wilmington, N.C., added Marye Anne Fox to its board.
ProdiGene Inc., of College Station, Texas, said its CEO and president, Anthony Laos, was appointed by President George W. Bush to serve as a member of the Board for International Food and Agriculture Development.
Ricerca Biosciences LLC, of Concord, Ohio, added Stanley Shotliff as chief financial officer, Detlef Rethage as executive vice president of operations and Stephen Adams as vice president of drug development biology.
Saegis Pharmaceuticals Inc., of Half Moon Bay, Calif., added Robert Gerlai as vice president of research.
Seattle Genetics Inc., of Bothell, Wash., promoted Peter Senter to vice president, chemistry.
Signature BioScience Inc., of San Francisco, appointed Robert Zimmerman chief operating officer and executive vice president, research and development, and Mary Ann Rafferty vice president, talent acquisition and development.
Structural GenomiX Inc., of San Diego, appointed Vicki Nienaber associate director for process technology and Leah Fung associate director in chemistry. Also, it added Karen Silva as director of corporate communications and investor relations.
Sunesis Pharmaceuticals Inc., of South San Francisco, appointed Duncan Walker vice president, discovery biology and promoted Robert McDowell to vice president, discovery chemistry.
SuperGen Inc., of Dublin, Calif., appointed Michael Young to its board.
The Indiana Proteomics Consortium, of Indianapolis, named Peter Kissinger, William Hunt and Jack Gill to its board.
Therion Biologics Corp., of Cambridge, Mass., added George Eldridge as chief financial officer, Suman Patel as vice president, quality, and Erin Quinn as vice president, human resources.
Transkaryotic Therapies Inc., of Cambridge, Mass., appointed John Edwards vice president, marketing and Linda Pettingell vice president, human resources. It also promoted William Aliski to vice president, commercial operations.
United Therapeutics Corp., of Silver Spring, Md., appointed Louis Sullivan to its board.
ViaCell Inc., of Boston, elected Jan van Heek to its board.
ViaLogy Corp., of Pasadena, Calif., added Jim Slater to its board.
Warnex Inc., of Montreal, added Hubert Carrier to its board.